资本赋能 科创板科创成长层创新药企打造发展新范式

Core Viewpoint - Innovative biopharmaceutical company "He Yuan Bio" is set to be listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board, marking the first company to pass the review under the fifth set of standards since its restart [1] Group 1: Company Overview - He Yuan Bio is the first company to be approved for listing under the fifth set of standards, which allows for the issuance of shares by companies without revenue or profitability [1] - The fifth set of standards has facilitated numerous innovative pharmaceutical companies in overcoming funding bottlenecks and accelerating the development of innovative drugs [1] Group 2: Industry Impact - Since 2019, the cumulative financing scale of China's innovative drug industry in both primary and secondary markets has exceeded 1 trillion yuan [1] - The influx of capital has led to unprecedented activity in innovative drug research and development, with China's R&D pipeline accounting for approximately 25% of the global total [1] Group 3: Market Performance - Currently, there are 13 innovative pharmaceutical companies in the Sci-Tech Innovation Board's growth tier, with a total market capitalization of nearly 500 billion yuan [1] - These companies have collectively driven 25 new drug approvals since their listing, indicating a shift from R&D investment to commercialization [1] Group 4: Financial Projections - The innovative pharmaceutical companies are projected to achieve a total operating revenue of 31.9 billion yuan in 2024, representing a year-on-year growth of 54.39% [1] - They have successfully launched 20 new Class 1 drugs with "global new" attributes and have received "breakthrough therapy" designation for 10 innovative drugs across 17 indications from the National Medical Products Administration [1]